Pediatric endocrinologists embrace once-weekly somatrogon as preferred treatment for growth hormone deficiency

Pediatric endocrinologists, based on a survey involving 24 professionals from 12 countries, overwhelmingly prefer once-weekly somatrogon over the standard once-daily recombinant human growth hormone (rhGH) for the treatment of pediatric growth hormone deficiency (pGHD).

The study indicates that physicians find once-weekly somatrogon more convenient, less burdensome, and associated with higher satisfaction levels compared to once-daily rhGH.

Factors such as reduced injection frequency, decreased patient and caregiver burden, increased convenience, and improved adherence contribute to the positive perception of once-weekly somatrogon.

This preference suggests a potential shift in the standard of care for pGHD treatment in favor of this long-acting growth hormone.

Reference
Gomez R, Lamoureux R, Turner-Bowker DM, et al. Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study. Front Endocrinol (Lausanne). 2023;14:1254424. doi: 10.3389/fendo.2023.1254424. PMID: 37955005; PMCID: PMC10634585.